ArticleJournal of personalized medicine2022
Melatonin Reduces Alcohol Drinking in Rats with Disrupted Function of the Serotonergic System.
Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
- Exogenous Melatonin as a Sleep-promoting Agent beyond its Chronobiotic Properties: A Scoping Review of its Effects on Key Sleep-wake Neurotransmitters.Current neuropharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The reason for the limited treatment success of substance-use-related problems may be a causal heterogeneity of this disorder that, at least partly, is manifested as differences in substance-use motives between individuals. The aim of the present study was to assess if rats with pharmacologically induced differences in the function of the serotonergic system would respond differently to melatonin treatment compared to control rats with respect to voluntary alcohol consumption. To achieve this goal, we treated rats neonatally with the selective serotonin transporter (SERT) inhibitor escitalopram. This procedure has been reported to cause long-lasting sleep abnormalities in rodents. The study demonstrated that during adulthood, rats that had been treated with escitalopram tended to drink higher amounts of alcohol compared to control rats. Further, administration of melatonin significantly decreased the alcohol intake in escitalopram-treated animals but caused only a slight, nonsignificant reduction in the alcohol consumption by control rats. In conclusion, our data support the therapeutic potential of melatonin as a treatment for alcohol use disorder. However, interindividual differences between alcohol users may considerably modify the outcome of the melatonin treatment, whereby patients that manifest lower sleep quality due to disruption of serotonergic activity are more likely to benefit from this treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.